acamprosate


Also found in: Wikipedia.

acamprosate

an antialcoholic agent.
indications This drug is used for maintenance of abstinence from alcohol in alcohol dependence.
contraindications Severe renal disease, creatinine clearance of less than 30 mL per hour, and known hypersensitivity to this drug prohibit its use.

acamprosate

A drug used to assist in the control of alcoholism. Acamprosate has been found to be an effective and well-tolerated adjunct to the management of alcoholism. A brand name is Campral EC.
References in periodicals archive ?
Naltrexone or acamprosate should be offered as first-line pharmacologic therapy to patients with moderate to severe alcohol use disorder who do not respond to nonpharmacologic therapy alone, according to a practice guideline published by the American Psychiatric Association.
2 gram delayed-release tablets, and over the course of the year the company has launched several other products such as acamprosate delayed-release tablets, methotrexate tablets, olmesartan tablets and oseltamivir capsules.
It is advisable to start with an FDA-approved medication such as disulfiram for the motivated patient who has a collaborator and desires complete abstinence; naltrexone for a patient who wants to cut down on intake (a long-acting formulation can be used for poorly adherent patients); and acamprosate for a patient with at least some established sobriety who needs help with post-withdrawal sleep disturbances.
Acamprosate (calcium acetylhomotaurinate, brand name Campral) is an amino acid (homotaurine) derivative.
Acamprosate calcium and nalmefene work by reducing cravings for alcohol.
The evidence for acamprosate is not quite as strong.
2014): oral and long-acting injectable naltrexone, acamprosate, and disulfiram.
The anti-craving pill acamprosate appears to calm stress-related brain chemicals in certain people.
Kranzler referred to a recently published meta-analysis indicating that topiramate had a greater effect than did acamprosate or naltrexone in people with alcohol use disorders (Alcohol Clin.
This funding supports the continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia (TD).
They found that two drugs, acamprosate (brand name Campral) and oral naltrexone (brand name Revia), have the best evidence supporting their benefits.
Some patients may be open to receiving treatment by primary care providers, but few drugs are available (naltrexone, acamprosate, and disulfiram).